Risks and features of secondary infections in severe and critical ill COVID-19 patients
Haocheng Zhang(Fudan University), Wenhong Zhang(Fudan University), Jingwen Ai(Fudan University), Chao Qiu(Fudan University), Richeng Mao(Fudan University), Mingquan Guo(Shanghai Public Health Clinical Center), Haili Chen(Wenzhou Medical University), Jing Wu(Jiangnan University), Yi Zhang(Tianjin Medical University General Hospital), Yang Li(Ministry of Education of the People's Republic of China), Shu Chen(First Affiliated Hospital of Xi'an Jiaotong University), Zhaoqin Zhu(Shanghai Medical College of Fudan University), Feng Sun(Guangzhou University of Chinese Medicine), Xin Li(Peking University), Xian Zhou(Western Sydney University)
Cited by 6
Related Papers
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
|The Lancet|2020|29.1k
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
|Cellular Physiology and Biochemistry|2017|4.1k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Roles of IFN-γ in tumor progression and regression: a review
|Biomarker Research|2020|1.2k